Related Experiment Video
Updated: Oct 7, 2025
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Therapeutic Potential of Emodin for Gastrointestinal Cancers
Sierra J McDonald1, Brandon N VanderVeen1,2, Kandy T Velazquez1
1University of South Carolina, Columbia, SC, USA.
Abstract:
Gastrointestinal (GI) cancers cause one-third of all cancer-related deaths worldwide. Natural compounds are emerging as alternative or adjuvant cancer therapies given their distinct advantage of manipulating multiple pathways to both suppress tumor growth and alleviate cancer comorbidities; however, concerns regarding efficacy, bioavailability, and safety are barriers to their development for clinical use. Emodin (1,3,8-trihydroxy-6-methylanthraquinone), a Chinese herb-derived anthraquinone, has been shown to exert anti-tumor effects in colon, liver, and pancreatic cancers. While the mechanisms underlying emodin's tumoricidal effects continue to be unearthed, recent evidence highlights a role for mitochondrial mediated apoptosis, modulated stress and inflammatory signaling pathways, and blunted angiogenesis. The goals of this review are to (1) highlight emodin's anti-cancer properties within GI cancers, (2) discuss the known anti-cancer mechanisms of action of emodin, (3) address emodin's potential as a treatment complementary to standard chemotherapeutics, (4) assess the efficacy and bioavailability of emodin derivatives as they relate to cancer, and (5) evaluate the safety of emodin.
Insights
Emodin, a natural compound from Chinese herbs, shows promise in fighting gastrointestinal cancers by targeting multiple tumor pathways. Further research is needed to optimize its efficacy, delivery, and safety for clinical use.
Area of Science:
- Oncology
- Pharmacology
- Natural Products Chemistry
Background:
- Gastrointestinal (GI) cancers are a leading cause of cancer mortality globally.
- Natural compounds offer multi-pathway therapeutic advantages for cancer treatment.
- Emodin, a plant-derived anthraquinone, exhibits anti-tumor activity in various GI cancers.
Purpose of the Study:
- To review emodin's anti-cancer properties in GI cancers.
- To elucidate emodin's mechanisms of action against cancer.
- To assess emodin derivatives' efficacy, bioavailability, and safety for potential clinical application.
Main Methods:
- Literature review of emodin's anti-cancer effects and mechanisms.
- Analysis of studies on emodin derivatives in cancer models.
- Evaluation of safety and pharmacokinetic data for emodin and its derivatives.
Main Results:
- Emodin demonstrates anti-tumor effects through mitochondrial apoptosis, modulation of stress/inflammatory pathways, and inhibition of angiogenesis.
- Emodin derivatives show potential for improved efficacy and bioavailability.
- Safety profiles require careful consideration for clinical translation.
Conclusions:
- Emodin holds potential as an adjuvant therapy for GI cancers.
- Optimizing emodin derivatives is crucial for enhancing therapeutic outcomes.
- Comprehensive safety and efficacy evaluations are necessary before clinical adoption.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
02:38Mitogens and the Cell Cycle
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:15Drugs that Stabilize Microtubules